Press Release September 28, 2021Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate 0 0 Share
Company Ticker News September 23, 2021Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst 0 0 Share
Company Ticker News September 23, 2021Needham Turns Bullish on Biogen Stock, Call Traders Respond 0 0 Share
Press Release September 21, 2021Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience 0 0 Share
Press Release September 20, 2021FDA Approves Samsung Bioepis and Biogen's BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) 0 0 Share
Press Release September 17, 2021CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis 0 0 Share
Company Ticker News September 17, 2021Will Biogen Stock Come Back Amid Pessimism Surrounding Aduhelm Rollout? 0 0 Share
Press Release September 16, 2021Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy 0 0 Share
Company Ticker News September 15, 2021Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know 0 0 Share
Press Release September 15, 2021Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam) 0 0 Share
